Oragenics Announces Pricing of Public Offering
February 27 2024 - 8:25PM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”), a company focused on developing unique, intranasal
nanoparticle pharmaceuticals for the treatment of neurological
disorders, today announced the pricing of an underwritten public
offering of 1,400,000 shares of its common stock at a public
offering price of $1.50 per share, for gross proceeds of $2.1
million, before deducting underwriting discounts and offering
expenses payable by the Company. In addition, the Company has
granted the underwriters a 45-day option to purchase up to an
additional 210,000 shares of its common stock at the public
offering price, less discounts, to cover over-allotments, if any.
The offering is expected to close on March 1, 2024, subject to
satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the offering to
fund the continued development of ONP-002, which is a unique
neurosteroid drug compound intended to treat mild traumatic brain
injuries also known as concussions, and for general corporate
purposes and working capital.
ThinkEquity and Laidlaw & Company (UK) Ltd. are acting as
joint book-running managers for the offering.
The securities are being offered and sold pursuant to a shelf
registration statement on Form S-3 (File No. 333-269225), including
a base prospectus, filed with the Securities and Exchange
Commission (the “SEC”) on January 13, 2023 and declared effective
on January 25, 2023. The offering is being made only by means of a
written prospectus. A final prospectus supplement and accompanying
base prospectus describing the terms of the offering will be filed
with the SEC and available on its website at www.sec.gov. Copies of
the final prospectus supplement and the accompanying base
prospectus relating to the offering may also be obtained, when
available, from the offices of ThinkEquity, 17 State Street, 41st
Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Oragenics
Oragenics is a development-stage biotechnology company focused
on nasal delivery of pharmaceutical medications in neurology and
fighting infectious diseases, including drug candidates for
treating mild traumatic brain injury (mTBI), also known as
concussion, and for treating Niemann Pick Disease Type C (NPC), as
well as proprietary powder formulation and an intranasal delivery
device. For more information, please visit www.oragenics.com.
Forward Looking Statements
This press release contains “forward-looking statements” that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as “anticipate,” “believe,” “contemplate,” “could,”
“estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “target,” “aim,” “should,”
"will” “would,” or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on the Company’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully in the Company’s
public filings and in the documents incorporated or deemed to be
incorporated by reference therein. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no duty to update such information except as
required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227469715/en/
Oragenics, Inc. Janet Huffman, Chief Financial Officer
813-286-7900 jhuffman@oragenics.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024